Literature DB >> 8726234

First trimester prenatal diagnosis of Smith-Lemli-Opitz syndrome (7-dehydrocholesterol reductase deficiency).

K Mills1, H Mandel, R Montemagno, P Soothill, R Gershoni-Baruch, P T Clayton.   

Abstract

In Smith-Lemli-Opitz syndrome (SLOs), 7-dehydrocholesterol (7-DHC) accumulated because there is a block in the pathway for synthesis of cholesterol via 7-DHC. Prenatal diagnosis of SLOs has been achieved by analysis of 7-DHC in amniotic fluid obtained at 16-18 wk from pregnancies at risk. The purpose of this study was to investigate 7-DHC and cholesterol concentrations in chorionic villus (CV) samples with a view to performing first trimester prenatal diagnosis. Using a sensitive gas chromatography-mass spectrometry assay it was possible to detect 7-DHC in CV samples obtained as early as 7 wk of gestation. The ration of 7-DHC to cholesterol in placental tissue was shown to be relatively constant over the gestational period of 7-18 wk. We therefore proceeded to analyze the 7-DHC/cholesterol ration in CV samples taken at 10-12 wk of gestation from three pregnancies at risk for SLOs. The results were as follows: patient A, 1.10 x 10(-3); patient B, 1.80 x 10(-3); patient C, 0.091; control range for CVS (8-12 wk), 3.10 x 10(-4) to 1.62 x 10(-3) (mean +/- 2SD; n = 5). The fetus of patient C was diagnosed as affected by SLOs, and the parents requested termination. Analysis of cultured skin fibroblasts confirmed the diagnosis. Pregnancies A and B were diagnosed unaffected, and this was confirmed first by amniocentesis and then by the birth of normal infants at term. We conclude that synthesis of cholesterol via 7-DHC is occurring in the placenta and/or fetus at 10 wk of gestation and that prenatal diagnosis by CV biopsy is possible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726234     DOI: 10.1203/00006450-199605000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

Review 1.  Disorders of cholesterol biosynthesis.

Authors:  P T Clayton
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

2.  Smith-Lemli-Opitz syndrome: deficient delta 7-reductase activity in cultured skin fibroblasts and chorionic villus fibroblasts and its application to pre- and postnatal detection.

Authors:  R J Wanders; G J Romeijn; F Wijburg; R C Hennekam; J de Jong; R A Wevers; G Dacremont
Journal:  J Inherit Metab Dis       Date:  1997-07       Impact factor: 4.982

3.  Highly increased CSF concentrations of cholesterol precursors in Smith-Lemli-Opitz syndrome.

Authors:  A van Rooij; A A Nijenhuis; F A Wijburg; R B Schutgens
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

4.  Smith-Lemli-Opitz Mutations in Unexplained Stillbirths.

Authors:  Karen J Gibbins; Uma M Reddy; George R Saade; Robert L Goldenberg; Donald J Dudley; Corette B Parker; Vanessa Thorsten; Halit Pinar; Radek Bukowski; Carol J Hogue; Robert M Silver
Journal:  Am J Perinatol       Date:  2018-02-12       Impact factor: 1.862

5.  Protein profiling underscores immunological functions of uterine cervical mucus plug in human pregnancy.

Authors:  Deug-Chan Lee; Sonia S Hassan; Roberto Romero; Adi L Tarca; Gaurav Bhatti; Maria Teresa Gervasi; Joseph A Caruso; Paul M Stemmer; Chong Jai Kim; Lea Kirstine Hansen; Naja Becher; Niels Uldbjerg
Journal:  J Proteomics       Date:  2011-03-23       Impact factor: 4.044

6.  Relation between biomarkers and clinical severity in patients with Smith-Lemli-Opitz syndrome.

Authors:  Anna V Oláh; Gabriella P Szabó; József Varga; Lídia Balogh; Györgyi Csábi; Violetta Csákváry; Wolfgang Erwa; István Balogh
Journal:  Eur J Pediatr       Date:  2013-01-15       Impact factor: 3.183

7.  Potential of sterol analysis by liquid chromatography-tandem mass spectrometry for the prenatal diagnosis of Smith-Lemli-Opitz syndrome.

Authors:  William J Griffiths; Yuqin Wang; Kersti Karu; Emmanuel Samuel; Shane McDonnell; Martin Hornshaw; Cedric Shackleton
Journal:  Clin Chem       Date:  2008-06-12       Impact factor: 8.327

8.  Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype.

Authors:  A K Ryan; K Bartlett; P Clayton; S Eaton; L Mills; D Donnai; R M Winter; J Burn
Journal:  J Med Genet       Date:  1998-07       Impact factor: 6.318

9.  Smith-Lemli-Opitz syndrome - Fetal phenotypes with special reference to the syndrome-specific internal malformation pattern.

Authors:  Katharina Schoner; Martina Witsch-Baumgartner; Jana Behunova; Robert Petrovic; Rainer Bald; Susanne G Kircher; Annette Ramaswamy; Britta Kluge; Matthias Meyer-Wittkopf; Ralf Schmitz; Barbara Fritz; Johannes Zschocke; Franco Laccone; Helga Rehder
Journal:  Birth Defects Res       Date:  2019-12-16       Impact factor: 2.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.